Back to top
more

Mersana Therapeutics (MRSN)

(Delayed Data from NSDQ)

$3.17 USD

3.17
1,487,451

+0.01 (0.32%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $3.18 +0.01 (0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mersana Stock Spikes on Interim Data on Cancer Candidate

Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.

Why Mersana Therapeutics (MRSN) Stock Might be a Great Pick?

Mersana Therapeutics (MRSN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Madeleine Johnson headshot

Why Mersana Therapeutics (MRSN) Spiked 69% Today

Shares of biotech firm Mersana Therapeutics (MRSN) soared on Wednesday, closing up 69% to $18.19 per share. What was the cause

Top Ranked Momentum Stocks to Buy for May 20th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 20th.

Top Ranked Momentum Stocks to Buy for May 13th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 13th.

Top Ranked Momentum Stocks to Buy for April 20th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th

Top Ranked Momentum Stocks to Buy for April 14th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 14th

Will Mersana Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Mersana Therapeutics.

Mersana Therapeutics (MRSN) Looks Good: Stock Adds 5.8% in Session

Mersana Therapeutics (MRSN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out for

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?

Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.